These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 5259

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Disposition and biotransformation of 14 C-oxisuran in the dog.
    Crew MC, Melgar MD, Haynes LJ, Gala RL, Di Carlo FJ.
    Xenobiotica; 1972 Sep; 2(5):431-40. PubMed ID: 4649040
    [No Abstract] [Full Text] [Related]

  • 6. Metabolism of oxisuran, an immunosuppressant, by the rat.
    Di Carlo FJ, Crew MC, Haynes LJ, Gala RL.
    Xenobiotica; 1972 Mar; 2(2):159-68. PubMed ID: 5056813
    [No Abstract] [Full Text] [Related]

  • 7. Interspecies comparisons of oxisuran metabolism and pharmacokinetics.
    Di Carlo FJ.
    Drug Metab Rev; 1979 Mar; 10(2):225-37. PubMed ID: 399459
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Disposition and metabolism of the angiotensin-converting enzyme inhibitor [4S-[4 alpha, 7 alpha, (R*), 12b beta]]-7-[S-(1-ethoxycarbonyl-3- phenylpropyl)amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo- pyrido[2,1-a][2]benzazepine-4-carboxylic acid in monkeys and dogs.
    Cheng H, Stuhler JD, Dorrbecker BR, Gordon WP.
    Drug Metab Dispos; 1991 Mar; 19(1):212-7. PubMed ID: 1673401
    [Abstract] [Full Text] [Related]

  • 11. Oxisuran: influence on allograft rejection and graft versus host reactivity in chickens and mice.
    Bixler GS, Linna TJ.
    Immunopharmacology; 1982 Feb; 4(1):79-85. PubMed ID: 6895887
    [Abstract] [Full Text] [Related]

  • 12. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.
    Vickers S, Duncan CA, Arison BH, Davies RO, Ferguson R, Zacchei AG.
    Drug Metab Dispos; 1980 Feb; 8(3):163-7. PubMed ID: 6104580
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. New metabolites of sulfinpyrazone in man.
    Dieterle W, Faigle JW, Moppert J.
    Arzneimittelforschung; 1980 Feb; 30(6):989-93. PubMed ID: 7191279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of oxisuran on differential inhibition of cell-mediated immunity.
    Tan M, Nishihira T, Tsutsumi E, Kasai M.
    Tohoku J Exp Med; 1976 Aug; 119(4):333-7. PubMed ID: 134470
    [Abstract] [Full Text] [Related]

  • 18. [Chemical study on the pharmacokinetics of propiramfumarate].
    Pütter J, Kroneberg G.
    Arzneimittelforschung; 1974 Apr; 24(4):643-51. PubMed ID: 4406767
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C, Kamel A, Gummerus J, Wilner K.
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.